Axsome Therapeutics, Inc.

AXSM Nasdaq SEC CIK 1579428
Follow Axsome Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $259.7M +51.9% vs same quarter last year
Net income −$12.9M +72.7% vs same quarter last year
EPS, diluted −$0.25 +73.4% vs same quarter last year
Operating cash flow −$9.5M −1005.3% vs same quarter last year
Revenue by quarter
$118.8M
$121.5M
$150M
$171M
$196M
$191.2M
$218.4M
$259.7M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income13 fiscal years
  • Revenue
  • Net income
−$500M−$250M$0$250M$500M$750MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$638.5M−$183.2M
FY24$385.7M−$287.2M
FY23$270.6M−$239.2M
FY22$50M−$187.1M
FY21-−$130.4M
FY20-−$102.9M
FY19-−$68.3M
FY18-−$31M
FY17-−$28.9M
FY16-−$27.2M
FY15-−$12.2M
FY14-−$6M
FY13--
MarginsShare of revenue
  • Operating margin
  • Net margin
−400%−300%−200%−100%0%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−26.1%−28.7%
FY24−72.7%−74.5%
FY23−85.7%−88.4%
FY22−359.3%−374%
FY21--
FY20--
FY19--
FY18--
FY17--
FY16--
FY15--
FY14--
FY13--
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$93.9M
FY24−$128.7M
FY23−$145.7M
FY22−$117.2M
FY21−$108.5M
FY20−$78.5M
FY19−$46.4M
FY18−$30.1M
FY17−$26.5M
FY16−$21.4M
FY15−$7.5M
FY14-
FY13-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Axsome Therapeutics
  • Healthcare median
−400%−300%−200%−100%0%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearAxsome TherapeuticsHealthcare median
FY25−28.7%−30.6%
FY24−74.5%−47%
FY23−88.4%−58%
FY22−374%−80.4%
FY21-−71.9%
FY20-−62.2%
FY19-−46.3%
FY18-−49.6%
FY17-−45.9%
FY16-−36%
FY15-−38.4%
FY14-−35.5%
FY13-−37.1%